Taiho Oncology, Inc.

🇺🇸United States

Country: 🇺🇸United States

Ownership: Subsidiary

Established: 2002-01-01

Employees: 251

Market Cap: -

Website: http://www.taihooncology.com

Clinical Trials

A Study Evaluating TAS-102 Plus Nivolumab in Patients With MSS CRC

Phase 2

Completed

Conditions: Refractory Metastatic Colorectal Cancer

Interventions: Drug: TAS-102
Drug: nivolumab

First Posted Date: 2016-08-09

Last Posted Date: 2024-08-21

Lead Sponsor: Taiho Oncology, Inc.

Target Recruit Count: 18

Registration Number: NCT02860546

Locations: 🇺🇸
Florida Cancer Specialists, Sarasota, Florida, United States
🇺🇸
Sarah Cannon Research Institute, Nashville, Tennessee, United States
🇺🇸
Sarah Cannon Research Institute at HealthONE, Denver, Colorado, United States

A Randomized Phase 2 Trial of TAS-114 in Combination With S-1 Versus S-1

Phase 2

Completed

Conditions: Advanced or Metastatic Non-small Cell Lung Cancer

Interventions: Drug: TAS-114
Drug: S-1

First Posted Date: 2016-08-04

Last Posted Date: 2024-08-21

Lead Sponsor: Taiho Oncology, Inc.

Target Recruit Count: 128

Registration Number: NCT02855125

Study of TAS3681 in Metastatic Castration Resistant Prostate Cancer

Phase 1

Completed

Conditions: Metastatic Castration Resistant Prostate Cancer

Interventions: Drug: TAS3681

First Posted Date: 2015-10-02

Last Posted Date: 2024-06-27

Lead Sponsor: Taiho Oncology, Inc.

Target Recruit Count: 130

Registration Number: NCT02566772

Locations: 🇺🇸
Seattle Cancer Care Alliance, Seattle, Washington, United States
🇫🇷
Centre Léon BERARD, Lyon, France
🇫🇷
Institut Paoli Calmettes, Marseille, France

and more 30 locations

Phase 1-2 Study of ASTX660 in Subjects With Advanced Solid Tumors and Lymphomas

Phase 1

Active, not recruiting

Conditions: Solid Tumors
Lymphoma

Interventions: Drug: ASTX660

First Posted Date: 2015-07-21

Last Posted Date: 2024-12-04

Lead Sponsor: Taiho Oncology, Inc.

Target Recruit Count: 230

Registration Number: NCT02503423

Locations: 🇺🇸
West Penn Hospital, Pittsburgh, Pennsylvania, United States
🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States
🇺🇸
University of Washington, Seattle Cancer Care Alliance, Seattle, Washington, United States

and more 65 locations

Study of TAS-102 or Placebo Plus BSC in Patients With Metastatic Gastric Cancer

Phase 3

Completed

Conditions: Refractory Metastatic Gastric Cancer

Interventions: Drug: Placebo
Drug: TAS-102

First Posted Date: 2015-07-16

Last Posted Date: 2024-06-27

Lead Sponsor: Taiho Oncology, Inc.

Target Recruit Count: 507

Registration Number: NCT02500043

Locations: 🇺🇸
Los Angeles Cancer Network, Los Angeles, California, United States
🇺🇸
Alta Bates Summit Comprehensive Cancer Center, Berkeley, California, United States
🇺🇸
Banner MD Anderson Cancer Center, Gilbert, Arizona, United States

and more 136 locations

A Trial of TAS-114 in Combination With S-1

Phase 1

Completed

Conditions: Advanced Solid Tumors

Interventions: Drug: TAS-114
Drug: S-1

First Posted Date: 2015-05-27

Last Posted Date: 2024-06-27

Lead Sponsor: Taiho Oncology, Inc.

Target Recruit Count: 120

Registration Number: NCT02454062

Locations: 🇧🇪
Erasme University Hospital-ULB, Brussels, Belgium
🇮🇹
IRCCS San Marino IST, Genoa, Italy
🇨🇭
IOSI Istituto Oncologico della Svizzera Italiana, Bellinzona, Switzerland

and more 2 locations

An Investigation of TAS-119 Monotherapy

Phase 1

Terminated

Conditions: Advanced Solid Tumors

Interventions: Drug: TAS-119

First Posted Date: 2015-05-19

Last Posted Date: 2024-06-27

Lead Sponsor: Taiho Oncology, Inc.

Target Recruit Count: 74

Registration Number: NCT02448589

Locations: 🇺🇸
University Hospitals - Seidman Cancer Center, Cleveland, Ohio, United States
🇮🇹
San Raffaele Hospital, Milano, Italy
🇪🇸
START MADRID-FJD, Hospital Fundación Jiménez Díaz, Madrid, Spain

and more 3 locations

A Phase I Study of TAS-102 in Patients With Advanced Solid Tumors With Renal Impairment

Phase 1

Completed

Conditions: Advanced Solid Tumors

Interventions: Drug: TAS-102

First Posted Date: 2014-11-25

Last Posted Date: 2024-06-27

Lead Sponsor: Taiho Oncology, Inc.

Target Recruit Count: 43

Registration Number: NCT02301117

Locations: 🇺🇸
Cleveland Clinical Site, Cleveland, Ohio, United States
🇺🇸
Boston Clinical Site, Boston, Massachusetts, United States
🇷🇸
Sremska Kamenica Clinical Site, Sremska Kamenica, Serbia

and more 10 locations

A Phase I Study of TAS-102 in Patients With Advanced Solid Tumors With Hepatic Impairment

Phase 1

Completed

Conditions: Advanced Solid Tumors

Interventions: Drug: TAS-102

First Posted Date: 2014-11-25

Last Posted Date: 2024-06-27

Lead Sponsor: Taiho Oncology, Inc.

Target Recruit Count: 24

Registration Number: NCT02301104

Locations: 🇺🇸
Dallas Clinical Site, Dallas, Texas, United States
🇺🇸
Pittsburgh Clinical Site, Pittsburgh, Pennsylvania, United States
🇺🇸
Cleveland Clinical Site, Cleveland, Ohio, United States

and more 5 locations

Expanded Access Study of TAS-102 in Patients With Metastatic Colorectal Cancer

Conditions: Colorectal Cancer Metastatic

First Posted Date: 2014-11-07

Last Posted Date: 2024-06-27

Lead Sponsor: Taiho Oncology, Inc.

Registration Number: NCT02286492

Locations: 🇺🇸
The Mark H. Zangmeister Center, Columbus, Ohio, United States
🇺🇸
Ocala Oncology Center, Ocala, Florida, United States
🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States

and more 29 locations

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy